EMILY FOGEL: Open Payments
NPI 1982262788 · LAWRENCEBURG, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$461 in 25 payments from 8 companies in 2025. Trend: 2023 $175 · 2024 $425 · 2025 $461
Food & beverage: $461
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $110 |
| Verona Pharma, Inc. | 4 | $83 |
| GENZYME CORPORATION | 4 | $77 |
| GlaxoSmithKline, LLC. | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Pulmonx Corporation | 1 | $27 |
| Grifols USA, LLC | 1 | $16 |
Products named: DUPIXENT, Ohtuvayre, NUCALA, GLASSIA, TEZSPIRE, CHARTIS CATHETER, TRELEGY ELLIPTA, Prolastin-C Liquid.
Industry payments across IN — which companies pay providers there.
